In 2007, John Van Drie wrote a perspective on what the next two decades of progress in computer-assisted drug design (CADD) might entail. Ash Jogalekar recently looked back at this list, and rated the progress towards each of Van Drie’s goals on a scale from one to ten. There’s a lot in Jogalekar’s piece that’s interesting and worth discussing, but I was particularly intrigued by the sixth item on the list (emphasis added): Outlook 6: today’s sophisticated CADD tools only in the han...
